Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
Type:
Grant
Filed:
November 20, 2014
Date of Patent:
November 10, 2015
Assignees:
SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Abstract: The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence.
Type:
Application
Filed:
April 15, 2015
Publication date:
October 15, 2015
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence.
Type:
Application
Filed:
April 15, 2015
Publication date:
October 15, 2015
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.
Type:
Grant
Filed:
June 18, 2013
Date of Patent:
September 1, 2015
Assignee:
INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
Type:
Application
Filed:
May 7, 2015
Publication date:
August 27, 2015
Applicants:
Sumitomo Dainippon Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.
Abstract: The invention provides a method for testing a WT1-related disease, such as leukemia, a solid cancer, or an atypia, for diagnosing the disease, evaluating the course of cure and the prognosis of the disease more simply with high reliability, the method comprises measuring the amount of antibody against WT1 in a sample and using the measurement value and the time course of the value as a clinical marker for the testing.
Type:
Grant
Filed:
October 25, 2010
Date of Patent:
July 21, 2015
Assignee:
INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.
Type:
Grant
Filed:
June 18, 2013
Date of Patent:
April 14, 2015
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
Type:
Application
Filed:
November 20, 2014
Publication date:
March 19, 2015
Applicants:
Sumitomo Dainippon Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.
Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.
Type:
Grant
Filed:
December 31, 2013
Date of Patent:
February 3, 2015
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.
Type:
Grant
Filed:
December 31, 2013
Date of Patent:
January 13, 2015
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.
Type:
Application
Filed:
February 20, 2014
Publication date:
October 23, 2014
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.
Type:
Application
Filed:
February 20, 2014
Publication date:
October 23, 2014
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence.
Type:
Application
Filed:
June 20, 2012
Publication date:
September 11, 2014
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method.
Type:
Application
Filed:
September 13, 2012
Publication date:
August 14, 2014
Applicants:
OTSUKA PHARMACEUTICAL CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.
Type:
Application
Filed:
December 31, 2013
Publication date:
July 17, 2014
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and others.
Type:
Grant
Filed:
March 2, 2012
Date of Patent:
July 15, 2014
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.
Type:
Application
Filed:
December 31, 2013
Publication date:
July 10, 2014
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.
Type:
Application
Filed:
December 31, 2013
Publication date:
July 10, 2014
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method for the induction of a WT1-specific CTL using the peptide.
Type:
Grant
Filed:
February 21, 2007
Date of Patent:
June 24, 2014
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: The present invention provides a method for inducing antigen-specific T cells in a patient comprising administering to said patient in need thereof composition (a) which comprises an antigen protein or an antigen peptide as an active ingredient and composition (b) which comprises a non-specific immunopotentiator as an active ingredient, wherein composition (b) is administered in advance and then composition (a) is administered, as well as related pharmaceutical compositions.
Type:
Grant
Filed:
September 27, 2002
Date of Patent:
May 27, 2014
Assignee:
International Institute of Cancer Immunology, Inc.